[Value of pepsinogen I in serum as a screening method for early detection of gastroduodenal lesions and follow-up in therapy with non-steroidal antirheumatic drugs].
Gastroduodenal lesions of the mucosa are known to be the most frequent side effect during therapy with non-steroidal antiinflammatory drugs (NSAIDs). We investigated the radioimmunological determination of serum-pepsinogen I as an indicator for the quality of the gastroduodenal mucosa. A good correlation was found between the endoscopy findings of 78 patients and contemporary determinations of serum-pepsinogen. Further, a follow-up of pepsinogen I was made during the treatment of 107 patients with degenerative rheumatic diseases with eight different NSAIDs. The results recommend the determination of pepsinogen I as an indicator of gastroduodenal mucosal changes under therapy with NSAIDs; this determination gives a deciding factor for the gastrolesive potency of an NSAID.
Kullich
W
W
Ludwig Boltzmann Institut für Rehabilitation interner Erkrankungen, Saalfelden.
Pöllmann
G
G
Zmerekar
C
C
Klein
G
G
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005773:Gastroscopy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010435:Pepsinogens / Q000097:blood*; D010437:Peptic Ulcer / Q000097:blood / Q000139:chemically induced* / Q000517:prevention & control; D012307:Risk Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010435:Pepsinogens
Stellenwert der Bestimmung von Pepsinogen I im Serum als Screeningmethode zur Früherkennung gastroduodenaler Läsionen und als Verlaufskontrolle unter der Therapie mit nicht-steroidalen Antirheumatika.